湖南海利(600731.SH):子公司擬投建年產4000噸甲萘威和5000噸甲基硫菌靈等系列產品及配套年產3萬噸光氣建設項目
格隆匯2月25日丨湖南海利(600731.SH)公佈,根據公司戰略規劃的需要,進一步發展公司優勢產業,推進公司產品結構優化,加快產業升級,公司決定以全資子公司寧夏海利科技有限公司(簡稱“寧夏海利”)為實施主體,投資建設年產4000噸甲萘威和5000噸甲基硫菌靈等系列產品及配套年產3萬噸光氣建設項目。項目建成後,將成為公司新利潤增長點,將進一步提升公司的核心競爭力。項目總投資10.36億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.